---
title: "Deploying AI in Regulated Industries: Healthcare, Finance, and the Compliance Minefield"
description: "AI deployment in healthcare and financial services faces regulatory requirements that don't apply to consumer applications. Understanding the constraints before starting is cheaper than discovering them after deployment."
date: 2027-11-12
tags: ["AI & MLOps", "Enterprise AI", "Architecture"]
format: article
---

AI deployment in healthcare and financial services is not just harder than consumer AI — it is categorically different. The regulatory environment, data handling requirements, explainability mandates, and liability exposure change the design requirements substantially.

Organizations that begin AI projects in regulated industries without understanding the regulatory context tend to discover constraints late in the project cycle, when changes are most expensive.

## Healthcare: HIPAA, clinical AI, and the FDA

**HIPAA applies to AI systems that use protected health information (PHI)**. Any AI system trained on, fine-tuned with, or processing PHI must be deployed within a HIPAA-compliant environment (Business Associate Agreements with cloud providers, encrypted storage and transmission, access controls, audit logging). This applies even if the model itself doesn't store PHI — inference requests containing patient data must be handled in a compliant way.

The practical implication: consumer AI APIs (OpenAI, Anthropic direct API) are not HIPAA-compliant without a Business Associate Agreement. Azure OpenAI Service and AWS Bedrock offer HIPAA-eligible configurations. Verify BAA coverage before ingesting PHI into any AI system.

**Clinical decision support software may be regulated as a medical device**. The FDA's Software as a Medical Device (SaMD) framework applies to software that provides recommendations or diagnoses that clinicians rely on. AI that suggests diagnoses, predicts deterioration risk, or recommends treatment protocols may require FDA clearance (510(k)) or approval before deployment. The distinction between "providing information" (generally unregulated) and "making clinical decisions" (potentially regulated) is an area where legal guidance is essential.

**Bias and disparate impact in clinical AI is a safety issue**. Clinical models trained on data from specific demographic populations may perform poorly on underrepresented groups. This is not just an ethical concern — it is a patient safety concern with regulatory implications. Pre-deployment validation across demographic groups is essential, and ongoing monitoring for performance drift across patient populations is a clinical governance requirement.

## Financial services: model risk management and explainability

**Model Risk Management (MRM)**: US banking regulators (OCC, Federal Reserve, FDIC) have published guidance (SR 11-7) on model risk management that applies to models used in credit decisions, fraud detection, anti-money-laundering, and other regulated functions. MRM requires:

- Model documentation covering design, assumptions, and limitations
- Independent validation (separate from the team that built the model)
- Ongoing monitoring and performance tracking
- Defined escalation for model performance problems

AI and ML models are explicitly covered by SR 11-7. Financial institutions deploying LLMs in regulated use cases should expect MRM teams to require documentation and validation that is more extensive than standard software review.

**Explainability requirements for credit decisions**: the Equal Credit Opportunity Act (ECOA) and the Fair Credit Reporting Act (FCRA) require that adverse credit decisions include specific reasons. "A black-box model rejected you" is not legally sufficient. This creates a real constraint on using complex models for credit decisions — either the model must support explainability (SHAP values, LIME), or a hybrid approach (explainable model for the decision; complex model for flagging) is needed.

**GDPR and financial data**: for EU customers, GDPR's right to explanation applies. Automated decisions that significantly affect individuals must be explainable and subject to human review on request. Design for this from the beginning; retrofitting explainability into deployed models is difficult.

## Cross-industry: the EU AI Act

The EU AI Act (fully effective in 2027, with earlier deadlines for specific provisions) establishes risk categories for AI systems operating in the EU:

**Prohibited AI**: social scoring by governments, real-time biometric surveillance in public spaces, AI that exploits vulnerabilities of specific groups, emotion recognition in employment/education.

**High-risk AI** (requiring conformity assessment): AI used in credit scoring, employment and HR decisions, biometric verification, critical infrastructure management, law enforcement, medical devices, education assessment, and migration/asylum decisions. High-risk AI must have human oversight, technical robustness, training data governance, and risk management systems.

**Limited-risk AI**: chatbots and AI systems that interact with humans must disclose that they are AI.

Healthcare and financial services applications frequently fall into the high-risk category. Compliance with the EU AI Act for high-risk systems requires documentation, conformity assessment, and post-market monitoring that is substantially more demanding than standard software governance.

## The pre-deployment checklist for regulated AI

Before deploying AI in a regulated context:

1. Identify applicable regulations and guidance documents
2. Determine whether the AI system constitutes a regulated product (medical device, financial model) or uses regulated data (PHI, credit data)
3. Engage legal and compliance teams early — not after the model is built
4. Design data handling, access controls, and audit logging for compliance from the start
5. Plan for explainability requirements in the model selection and design phase
6. Define the independent validation process (who will validate, what they will validate, what criteria must be met)
7. Establish production monitoring requirements before deployment

The cost of discovering a regulatory constraint after building and testing is a fraction of the cost of discovering it after deployment.

*Deploying AI in healthcare, financial services, or another regulated domain? The compliance architecture decisions have long-term implications. [Happy to share what the implementation looks like.](/contact)*
